Alkermes plc buy melinda
Start price
19.06.17
/
50%
€51.55
Target price
05.07.17
€54.12
Performance (%)
5.28%
End price
05.07.17
€54.27
Summary
This prediction ended on 05.07.17 with a price of €54.27. The BUY prediction by melinda finished with a performance of 5.28%. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Alkermes plc | 0.704% | 0.704% | 17.213% | 12.598% |
| iShares Core DAX® | -0,37 % | 8,40 % | 6,76 % | 47,91 % |
| iShares Nasdaq 100 | 2,27 % | 15,23 % | 36,18 % | 94,08 % |
| iShares Nikkei 225® | 1,43 % | 14,42 % | 43,11 % | 64,80 % |
| iShares S&P 500 | 1,22 % | 10,49 % | 27,28 % | 66,76 % |
Comments by melinda for this prediction
In the thread Alkermes plc diskutieren
genehmigt (FDA)
Die US Food and Drug Administration (FDA) genehmigt hat ALKERMES des zweimonatigen Aristada (Aripiprazol lauroxil) extended-release injizierbare Suspension zur Behandlung von Schizophrenie.